Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clarus Therapeutics Holdings, Inc.CRXT · Entity 126356 | Director | June 07, 2022 | June 09, 2022 |
| ORAGENICS INCOGEN · Entity 8495 | Director | September 19, 2024 | September 21, 2024 |
| Onconetix, Inc.BWV · Entity 8471 | Director | May 04, 2022 | May 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clarus Therapeutics Holdings, Inc.
Report date June 07, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,766 |
Reported balance
After 2022-06-07 transaction · row 1
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 1,922 · Balance 5,766 F1: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2032-06-06 | Direct | 4,805 |
Reported balance
After 2022-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-07 · Grant · Acquired 4,805 · Balance 4,805 F2: These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.
F2: These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.
ORAGENICS INC
Report date September 19, 2024 · Filed September 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Director Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2034-09-19 | Direct | 27,083 |
Reported balance
After 2024-09-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-09-19 · Grant · Acquired 27,083 · Balance 27,083 F1: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.
Onconetix, Inc.
Report date May 04, 2022 · Filed May 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.45 · Expires 2032-05-04 | Direct | 50,575 |
Reported balance
After 2022-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-04 · Grant · Acquired 4,655 · Balance 50,575 F1: Stock options (the "Options") were granted to Ms. Murphy on May 4, 2022. The Options vest and become exercisable as follows: (i) 774 of the Options vested immediately upon grant; (ii) 388 Options vest at the end of each calendar month from the date of issuance through February 28, 2023; and (iii) the remaining 389 Options vest on March 31, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options (the "Options") were granted to Ms. Murphy on May 4, 2022. The Options vest and become exercisable as follows: (i) 774 of the Options vested immediately upon grant; (ii) 388 Options vest at the end of each calendar month from the date of issuance through February 28, 2023; and (iii) the remaining 389 Options vest on March 31, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2024 Filed Sep 21, 2024 01:15 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 27,083 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001493152-24-037726 · ownership.xml · derivative · entry 1 Murphy Kimberly M · CIK 0001810474 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,083 Underlying: Common Stock · 27,083 shares Expires 2034-09-19 F1 · security: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · shares: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · derivative.exercise_date: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. F1 · balance_after: Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 20:30 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-027580 · ownership.xml · nonDerivative · entry 1 Murphy Kimberly M · CIK 0001810474 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Represents an award of restricted stock of the Company's common stock under the Company's 2021 Equity Incentive Plan in connection with serving as the Company President and Chief Executive Officer with 20,000 shares vesting immediately and 5,000 shares vesting in six (6) months. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:15 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantEmployee Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001493152-22-017712 · ownership.xml · derivative · entry 1 Murphy Kimberly M · CIK 0001810474 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2032-06-23 F1 · shares: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan in connection with the engagement to serve as the Company President and Chief Executive Officer. The options vest as follows: 160,000 options vest on the grant date, 160,000 options vest on December 23, 2022, 160,000 options vest on June 23, 2023, 160,000 options vest on December 23, 2023, and 160,000 options vest on June 23, 2024. The option exercise price is the Company's closing price on the date of grant. F1 · balance_after: Represents an award of options to purchase shares of the Company's common stock under the Company's 2021 Equity Incentive Plan in connection with the engagement to serve as the Company President and Chief Executive Officer. The options vest as follows: 160,000 options vest on the grant date, 160,000 options vest on December 23, 2022, 160,000 options vest on June 23, 2023, 160,000 options vest on December 23, 2023, and 160,000 options vest on June 23, 2024. The option exercise price is the Company's closing price on the date of grant. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:04 UTC | Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356 | GrantStock Option (Right to Buy) · Derivative | 4,805 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0000899243-22-021760 · doc4.xml · derivative · entry 2 Murphy Kimberly M · CIK 0001810474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Underlying: Common Stock · 4,805 shares Expires 2032-06-06 F2 · derivative.exercise_date: These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:04 UTC | Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356 | GrantCommon Stock | 1,922 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-021760 · doc4.xml · nonDerivative · entry 1 Murphy Kimberly M · CIK 0001810474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766 F1 · shares: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting. Read SEC document |
| May 04, 2022 Filed May 27, 2022 10:43 UTC | Onconetix, Inc. BWV · Entity 8471 | GrantStock Option · Derivative | 4,655 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001213900-22-029999 · ownership.xml · derivative · entry 1 Murphy Kimberly M · CIK 0001810474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,575 Underlying: Common Stock, par value $0.00001 per share · 4,655 shares Expires 2032-05-04 F1 · derivative.exercise_date: Stock options (the "Options") were granted to Ms. Murphy on May 4, 2022. The Options vest and become exercisable as follows: (i) 774 of the Options vested immediately upon grant; (ii) 388 Options vest at the end of each calendar month from the date of issuance through February 28, 2023; and (iii) the remaining 389 Options vest on March 31, 2023. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 21:10 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001493152-21-032033 · ownership.xml · derivative · entry 1 Murphy Kimberly M · CIK 0001810474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2021-12-16 F1 · security: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. F1 · shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. F1 · derivative.underlying_shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. F1 · balance_after: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, December 16, 2021. Read SEC document |
| December 12, 2021 Filed Dec 14, 2021 19:00 UTC | Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356 | GrantStock Option (Right to Buy) · Derivative | 9,610 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0000899243-21-048202 · doc4.xml · derivative · entry 2 Murphy Kimberly M · CIK 0001810474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,610 Underlying: Common Stock · 9,610 shares Expires 2031-12-11 F2 · derivative.exercise_date: These options were granted under the 2021 Plan and vest in equal annual installments over a period of three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting. Read SEC document |
| December 12, 2021 Filed Dec 14, 2021 19:00 UTC | Clarus Therapeutics Holdings, Inc. CRXT · Entity 126356 | GrantCommon Stock | 3,844 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-048202 · doc4.xml · nonDerivative · entry 1 Murphy Kimberly M · CIK 0001810474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,844 F1 · shares: The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 3,844 shares on 12/12/2021, which vests in equal annual installments over three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting date. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 21:37 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001493152-21-004425 · ownership.xml · derivative · entry 1 Murphy Kimberly M · CIK 0001810474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2031-02-18 F1 · security: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. F1 · shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. F1 · derivative.underlying_shares: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. F1 · balance_after: Represents an annual award of options pursuant to the Company's non-employee director compensation program to purchase shares of common stock under the Company's 2012 Equity Incentive Plan. The options vest immediately and the exercise price is the closing price on the date of the grant, February 18, 2021. Read SEC document |
| May 01, 2020 Filed May 4, 2020 21:17 UTC | ORAGENICS INC OGEN · Entity 8495 | GrantNon-Employee Director Option (Right to Buy) · Derivative | 138,664 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001493152-20-007670 · ownership.xml · derivative · entry 1 Murphy Kimberly M · CIK 0001810474 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,664 Underlying: Common Stock · 138,664 shares Expires 2030-05-01 F1 · security: Represents an initial equity award upon appointment to the Company's board of directors of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vests immediately. F1 · derivative.underlying_shares: Represents an initial equity award upon appointment to the Company's board of directors of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vests immediately. F1 · balance_after: Represents an initial equity award upon appointment to the Company's board of directors of options pursuant to the non-employee director compensation program to purchase shares of the Company's common stock under the Company's 2012 Equity Incentive Plan, as amended that vests immediately. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.